2020 Vision
563 What contributes to quality of life in Parkinson’s disease: a re-evaluation  
A Schrag, N Quinn

566 Too much of a good thing: hedonistic homeostatic dysregulation and other  
behavioural consequences of excessive dopamine replacement therapy in Parkinson’s disease  
J D O’Sullivan

Editorial comments
568 Neurology in the time of COVID-19  
H Manji, A S Carr, W J Brownlee, M P Lunn

571 Remember the null hypothesis?  
C Randolph

Autonomic
572 New insights in post-traumatic headache with  
crusted cluster headache phenotype: a cohort study  
L Grangene, E O’Connor, C-K Chau, L Abijian,  
T M Pham Ngoc, M S Matharu

Cerebrovascular disease
580 Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary  
intracerebral haemorrhage: population-based study  
L Li, R Luengo-Fernandez, S M Zuurbier,  
N C Beddows, L F Lavallée, I E Silver, W Kuker,  
P M Rothwell

Cognitive neurology
586 Clinical and neuropsychological profile of patients with dementia and chronic traumatic  
encephalopathy  
C LoBue, J Schaffer, C M Callum, M E Peters,  
N Dubeck, J Hart, C L White

Migraine
593 Migraine and risk of stroke  
L R One, T Kurth, S Galas, D W Dodick

Neuro-inflammation
605 CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative  
NMOSD  
I Kleerekooper, M K Herber, H B Kuiperj,  
D K Sato, K Fujikura, D Callegaro, R Manigier,  
A Saiz, M Senel, H Tumani, B A De Jong, S A Trij,  
I Nakashima, M M Verbeeck, A Petzold

Neurodegeneration
612 Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal  
dementia  
E L van der Ende, M Xiao, D Xu, J M Poos,  
J L Panman, C Jiskoot, L H Meeter,  
E G P Dopper, J M Papma, C Heller, R Convery,  
K Moore, M Bocchetta, M Neason, G Peakman,  
D M Cash, C E Teunissen, C Graff, S Symeotic,  
F Moreno, F Einger, R Sánchez-Valle,  
R Vandenberghe, R Lafenere Jr, M Maselis,  
M C Tartaglia, J B Rowe, C R Butler,  
S Ducharme, A Gerhardt, A Danej, J Levis,  
Y A1 Piipnenburg, M Otto, B Born,  
F Tagliavini, A de Mendonca, I Santana,  
D Galimberti, H Seelaar, J D Rohrer,  
P F Worsley, J C van Swieten, on behalf of the  
Genetic Frontotemporal Dementia Initiative  
(GENFI)

622 Antidopaminergic treatment is associated with reduced chorea and irritability but  
impaired cognition in Huntington’s disease (Enroll-HD)  
K L Harris, W-L Kuan, S L Mason, R A Barker

MORE CONTENTS

Contents
Volume 91 Issue 6 | JNNP June 2020

Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson’s disease
P O Jenkins, A-A Roussakis, S De Simoni, N Bourke, J Fleming, J Cole, P Piccini, D Sharp

Outcome measurement in functional neurological disorder: a systematic review and recommendations

Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome
H Koike, Y Fukami, R Nishi, Y Kawagashira, M Iijima, M Katsumo, G Sobue

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
H Butzkueven, L Kayppos, H Wiendl, M Trojano, T Spelman, I Cheng, R Kasliwal, S Jaitly, N Campbell, P R Ho, S Licata, On behalf of the Tysabri Observational Program (TOP) Investigators

Letters
M AJ Tijssen, M Tinazzi, T R Nicholson